Evidence map›Paper›PMID 29228063›Full record

ArticlePLoS pathogens2017

What matters in chronic Burkholderia cenocepacia infection in cystic fibrosis: Insights from comparative genomics.

Jaroslav Nunvar, Vaclav Capek, Karel Fiser, Libor Fila, Pavel Drevinek

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Genomic features, antimicrobial susceptibility, and epidemiological insights intoFrontiers in cellular and infection microbiology · 2023
    Article
  7. Adaptation and Evolution of Pathogens in the Cystic Fibrosis Lung.Journal of the Pediatric Infectious Diseases Society · 2022
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. One gene, multiple ecological strategies: A biofilm regulator is a capacitor for sustainable diversity.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  14. Article
  15. Comparative Evolutionary Patterns ofFrontiers in microbiology · 2020
    Article
  16. Article
  17. The Effect of 2-Thiocyanatopyridine Derivative 11026103 onAntibiotics (Basel, Switzerland) · 2019
    Article
  18. Frontiers in cellular and infection microbiology · 2019
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jaroslav NunvarDepartment of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Vaclav CapekBioinformatics Centre, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
Karel FiserDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.ORCID 0000-0002-7265-3268
Libor FilaDepartment of Pneumology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.ORCID 0000-0002-5036-4457
Pavel DrevinekDepartment of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.ORCID 0000-0002-8994-5240
Charles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burkholderia cenocepacia causes severe pulmonary infections in cystic fibrosis (CF) patients. Since the bacterium is virtually untreatable by antibiotics, chronic infections persist for years and might develop into fatal septic pneumonia (cepacia syndrome, CS). To devise new strategies to combat chronic B. cenocepacia infections, it is essential to obtain comprehensive knowledge about their pathogenesis. We conducted a comparative genomic analysis of 32 Czech isolates of epidemic clone B. cenocepacia ST32 isolated from various stages of chronic infection in 8 CF patients. High numbers of large-scale deletions were found to occur during chronic infection, affecting preferentially genomic islands and nonessential replicons. Recombination between insertion sequences (IS) was inferred as the mechanism behind deletion formation; the most numerous IS group was specific for the ST32 clone and has undergone transposition burst since its divergence. Genes functionally related to transition metal metabolism were identified as hotspots for deletions and IS insertions. This functional category was also represented among genes where nonsynonymous point mutations and indels occurred parallelly among patients. Another category exhibiting parallel mutations was oxidative stress protection; mutations in catalase KatG resulted in impaired detoxification of hydrogen peroxide. Deep sequencing revealed substantial polymorphism in genes of both categories within the sputum B. cenocepacia ST32 populations, indicating extensive adaptive evolution. Neither oxidative stress response nor transition metal metabolism genes were previously reported to undergo parallel evolution during chronic CF infection. Mutations in katG and copper metabolism genes were overrepresented in patients where chronic infection developed into CS. Among professional phagocytes, macrophages use both hydrogen peroxide and copper for their bactericidal activity; our results thus tentatively point to macrophages as suspects in pathogenesis towards the fatal CS.

Indexed as

Burkholderia cenocepaciaBurkholderia InfectionsChronic DiseaseComparative Genomic HybridizationCystic FibrosisHumansRespiratory Tract Infections

Identifiers

PMID29228063
PMCPMC5739508
OpenAlexW2774434528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.